ARJ is based in Mexico City, Mexico, and is also the largest player in the private pharmaceutical testing laboratory arena, as well a providing quality control for medicines, biological products, generics and biosmiliars.
Founded in 1967 it has been built up into a business with an annual revenue of $30 million and employs more than 500 people throughout the region.
New business serves as a region hub
While Mexico is itself a fast-growing market, it also serves as an important hub for all of the industries the business serves throughout the Latin American region, as well as North America.
Executives at ALS Life Sciences Latin America operations say that the addition of the ARJ business will serve to boost the companies regional and global presence by expanding its offering to clients.
The company says that the acquisition fits in line with its desire to grow its business in the fast-growing Latin American region through further acquisitions.
Targeting growth markets in the region
While the company feels that the location of the ARJ in the Mexico City is vital, as it is in the heart of one of the region’s most vital economic regions, it also well places the company to serve other key markets in the region.
Speaking about the deal, ALS managing director and CEO Raj Naran, said: “this is an important, strategic acquisition for us.”
“ARJ has a world class operation and client base which offers us a strong platform to continue to grow our presence in key markets including Argentina, Brazil, Colombia, and Mexico. We welcome the ARJ team to ALS and look forward to our collaboration with them throughout the region.”